2026-01-10 - Analysis Report
Okay, here's a comprehensive report on UnitedHealth Group (UNH) based on the data provided, presented in a clear and analytical format.

**1. Return Rate Comparison and Divergence Analysis**

*   **Ticker:** UNH (UnitedHealth Group Inc)
*   **Overview:** UnitedHealth Group is a diversified healthcare company providing health benefits and healthcare services.
*   **UNH Cumulative Return:** -17.77%
*   **S&P 500 (VOO) Cumulative Return:** 92.74%
*   **Divergence:**
    *   Max: 29.8
    *   Min: -124.6
    *   Current: -111.2
    *   Relative Divergence: 8.7

**Analysis:**

UNH has significantly underperformed the S&P 500. The cumulative return is dramatically lower, and the current divergence is substantial. The relative divergence of 8.7 indicates that the current divergence is near its historical worst relative to the given range.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD      | Alpha   | Beta | Cap(B) |
|------------|---------|----------|---------|------|--------|
| 2016-2018  | 22.0%   | 18.6%    | 19.0%   | 0.9  | 223.8  |
| 2017-2019  | 27.0%   | 18.6%    | 10.0%   | 0.9  | 264.1  |
| 2018-2020  | -41.0%  | 32.5%    | -62.0%  | 1.1  | 315.0  |
| 2019-2021  | 16.0%   | 32.5%    | -27.0%  | 1.1  | 451.1  |
| 2020-2022  | 0.0%    | 31.5%    | 2.0%    | 0.9  | 476.3  |
| 2021-2023  | 23.0%   | 13.4%    | 23.0%   | 0.5  | 472.9  |
| 2022-2024  | -24.0%  | 23.1%    | -44.0%  | 0.4  | 454.4  |
| 2023-2025  | -55.0%  | 58.5%    | -118.0% | 0.3  | 296.6  |

**Analysis:**

*   **Alpha:** UNH's alpha has fluctuated significantly. Recent periods (2022-2025 and 2023-2025) show substantial negative alpha, indicating underperformance compared to its benchmark after accounting for risk.
*   **Beta:**  The beta values have decreased over time, suggesting UNH has become less correlated with the overall market.  Beta decreased sharply recently, from 1.1 during 2018-2021 to 0.3 in 2023-2025.
*   **CAGR & MDD:** Recent years demonstrate substantial volatility, including large negative CAGR and significant maximum drawdowns (MDD).
*   **Capitalization:** Company's cap has been recently decreased.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 346.85
*   **Last Market Data:**
    *   Price: 343.98
    *   Previous Close: 346.85
    *   Change: -0.83
*   **5-day SMA:** 343.188
*   **20-day SMA:** 334.2975
*   **60-day SMA:** 336.1528

**Analysis:**

The stock price closed lower compared to the previous day. The 5-day SMA is above the 20-day and 60-day SMAs, which could be interpreted as a short-term upward trend. However, the fact that the 20-day SMA is below the 60-day SMA suggests a longer-term downward or sideways trend.

**3. Indicator Analysis**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 64.28 (Approaching overbought conditions, but not there yet)
*   **PPO:** 0.5975 (Positive, indicating short-term moving average is above long-term, but the value is relatively small.)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80)
*   **Recent Divergence Change (20 days):** 3.3 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** -236.1% (Significantly negative)

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI suggests that the stock is nearing overbought territory but isn't there yet.
*   The PPO is slightly positive, indicating a potential short-term upward trend.
*   The Hybrid Signal suggests a buying opportunity.
*   The significant drop in the price (change of -0.83 compared to the previous close) indicates recent fluctuation.
*   The dramatically negative expected return is a significant red flag.

**4. Recent News & Significant Events**

*   **Positive Sentiment:**
    *   "Evercore Analysts Love UnitedHealth Stock for 2026"
    *   "Why UnitedHealth Stock Bumped Higher Today"
    *   "UnitedHealth wins Outperform rating at Evercore ISI"
*   **Potential Concerns:**
    *   "Here’s What Hit UnitedHealth Group’s (UNH) Performance"
    *   "TPG said to be nearing a deal to buy UnitedHealth's Optum UK unit" (Potential business restructuring implications)
    *   "Trump eyes a meeting with health insurers ‘in a few days’" (Regulatory uncertainty)

**Analysis:**

The news presents a mixed picture. While some analysts are positive on UNH's prospects, there are also articles highlighting performance issues and potential uncertainties related to regulations and business restructuring.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.93 (~Buy)
*   **Number of Opinions:** 26
*   **Target Price (avg/high/low):** 393.85 / 444.00 / 280.00
*   **Recent Rating Changes:**  None provided in the available data.

**Analysis:**

Analyst consensus is generally positive, with a "Buy" rating and an average target price suggesting upside potential. However, the wide range between the high and low target prices indicates some uncertainty among analysts.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-10-28 | 2.59  | 113.16 B$  |
| 2025-08-11 | 3.76  | 111.62 B$  |
| 2025-05-07 | 6.9   | 109.58 B$  |
| 2024-11-04 | 6.56  | 100.82 B$  |
| 2025-10-28 | 6.56  | 100.82 B$  |

**Analysis:**

* Revenue has been growing consistently over the past quarters.
* EPS has fluctuated, with a recent decrease in the last reported quarter.
* There's a duplicate entry for 2025-10-28 with different EPS values. This needs clarification.

**6. Financial Information**

**Revenue and Profitability**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|----------------|
| 2025-09-30   | $113.16B   | 18.24%         |
| 2025-06-30   | $111.62B   | 17.93%         |
| 2025-03-31   | $109.58B   | 21.70%         |
| 2024-12-31   | $100.81B   | 21.14%         |
| 2024-09-30   | $100.82B   | 22.84%         |

**Capital and Profitability**

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-09-30   | $95.79B   | 2.45%     |
| 2025-06-30   | $94.72B   | 3.60%     |
| 2025-03-31   | $95.04B   | 6.62%     |
| 2024-12-31   | $92.66B   | 5.98%     |
| 2024-09-30   | $94.53B   | 6.41%     |

**Analysis:**

*   **Revenue:** Consistent revenue growth over the periods presented.
*   **Profit Margin:** Profit margins have decreased slightly recently.
*   **Equity:** Equity has remained relatively stable.
*   **ROE:** ROE has significantly decreased in the most recent quarter.

**7. Comprehensive Analysis**

Based on the data provided, here's a summary of the key findings and a comprehensive analysis:

*   **Underperformance:** UNH has significantly underperformed the S&P 500. The cumulative return divergence is substantial.
*   **Mixed Signals:** Technical indicators present a mixed picture. The RSI is approaching overbought, the PPO is slightly positive, and moving averages suggest potential short-term upward momentum but longer-term weakness.
*   **Analyst Sentiment:** Analyst consensus is generally positive, but target prices vary considerably, indicating uncertainty.
*   **Recent News:** Recent news is mixed, with positive analyst commentary balanced by concerns about performance, potential business restructuring, and regulatory uncertainty.
*   **Financials:** Revenue has grown, but profit margins and ROE have recently decreased.
*   **Major Concern:** The dramatically negative expected return (-236.1%) is a significant concern.  This suggests the model predicts substantial future underperformance.
*   **Overall:** The current outlook for UNH appears uncertain. While there are some positive signals (analyst ratings, recent short-term price movement), the underperformance against the S&P 500, negative expected return, and decreasing ROE raise significant concerns. Further research is warranted to understand the underlying drivers of these trends. The duplication of EPS figures in the earnings data also raises questions about data accuracy.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.